S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
Log in
NASDAQ:BIIB

Biogen Stock Forecast, Price & News

$275.84
-4.45 (-1.59 %)
(As of 01/15/2021 08:00 PM ET)
Add
Compare
Today's Range
$275.48
Now: $275.84
$282.44
50-Day Range
$240.17
MA: $248.53
$280.29
52-Week Range
$223.25
Now: $275.84
$374.99
Volume116,314 shs
Average Volume1.44 million shs
Market Capitalization$42.45 billion
P/E Ratio9.13
Dividend YieldN/A
Beta0.53
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops Opicinumab, BIIB061, and BIIB091 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB110, and BIIB100 to treat neuromuscular disorders; BIIB054 and BIIB094 for treating movement disorders; BIIB111 and BIIB112 for ophthalmology; Dapirolizumab pegol and BIIB059 to treat immunology and others; BIIB104 for neurocognitive disorders; BIIB093, TMS-007, and Natalizumab to treat acute neurology; BIIB074 and BIIB095 for pain; and SB11 biosimilar, which are under various stages of development. The company offers products through its sales force and marketing groups. It has collaborations with Genentech, Inc.; Ionis Pharmaceuticals, Inc.; Eisai Co., Ltd.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Acorda Therapeutics, Inc.; AbbVie Inc.; Skyhawk Therapeutics, Inc.; Neurimmune SubOne AG; Scribe Therapeutics Inc.; Sangamo Therapeutics Inc.; ISD Immunotech; and Sage Therapeutics, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Biogen logo

MarketRank

Overall MarketRank

2.10 out of 5 stars

Medical Sector

31st out of 67 stocks

Biological Products, Except Diagnostic Industry

3rd out of 4 stocks

Analyst Opinion: 3.1Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.9 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:BIIB
CUSIP09062X10
Phone617-679-2000
Employees7,400

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$14.38 billion
Cash Flow$39.98 per share
Book Value$73.93 per share

Profitability

Net Income$5.89 billion

Miscellaneous

Market Cap$42.45 billion
Next Earnings Date2/3/2021 (Confirmed)
OptionableOptionable
$275.84
-4.45 (-1.59 %)
(As of 01/15/2021 08:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BIIB News and Ratings via Email

Sign-up to receive the latest news and ratings for BIIB and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Biogen (NASDAQ:BIIB) Frequently Asked Questions

How has Biogen's stock price been impacted by COVID-19 (Coronavirus)?

Biogen's stock was trading at $294.25 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, BIIB stock has decreased by 6.3% and is now trading at $275.84.
View which stocks have been most impacted by COVID-19
.

Is Biogen a buy right now?

33 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last year. There are currently 5 sell ratings, 15 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Biogen stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BIIB, but not buy additional shares or sell existing shares.
View analyst ratings for Biogen
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Biogen?

Wall Street analysts have given Biogen a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Biogen wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Biogen's next earnings date?

Biogen is scheduled to release its next quarterly earnings announcement on Wednesday, February 3rd 2021.
View our earnings forecast for Biogen
.

How can I listen to Biogen's earnings call?

Biogen will be holding an earnings conference call on Wednesday, February 3rd at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Biogen's earnings last quarter?

Biogen Inc. (NASDAQ:BIIB) announced its quarterly earnings results on Wednesday, October, 21st. The biotechnology company reported $8.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $8.06 by $0.78. The biotechnology company had revenue of $3.38 billion for the quarter, compared to the consensus estimate of $3.34 billion. Biogen had a net margin of 35.63% and a return on equity of 51.00%. The firm's quarterly revenue was down 6.2% on a year-over-year basis. During the same quarter in the prior year, the business posted $9.17 EPS.
View Biogen's earnings history
.

How will Biogen's stock buyback program work?

Biogen declared that its board has authorized a stock buyback program on Monday, December 23rd 2019, which allows the company to buyback $5,000,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to repurchase shares of its stock through open market purchases. Stock buyback programs are generally an indication that the company's board of directors believes its shares are undervalued.

What guidance has Biogen issued on next quarter's earnings?

Biogen issued an update on its FY 2020 Pre-Market earnings guidance on Wednesday, October, 21st. The company provided earnings per share (EPS) guidance of 32.50-33.50 for the period, compared to the Thomson Reuters consensus estimate of $34.77. The company issued revenue guidance of $13.2-13.4 billion, compared to the consensus revenue estimate of $13.83 billion.

What price target have analysts set for BIIB?

33 analysts have issued twelve-month price objectives for Biogen's stock. Their forecasts range from $175.00 to $450.00. On average, they anticipate Biogen's share price to reach $306.13 in the next twelve months. This suggests a possible upside of 11.0% from the stock's current price.
View analysts' price targets for Biogen
or view Wall Street analyst' top-rated stocks.

Who are some of Biogen's key competitors?

What other stocks do shareholders of Biogen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biogen investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Amgen (AMGN), The Walt Disney (DIS), Intel (INTC), Micron Technology (MU) and The Boeing (BA).

Who are Biogen's key executives?

Biogen's management team includes the following people:
  • Mr. Michel Vounatsos, CEO & Director (Age 58, Pay $5.72M)
  • Ms. Susan H. Alexander, Exec. VP, Chief Legal Officer & Sec. (Age 63, Pay $1.99M)
  • Dr. Alfred W. Sandrock Jr., Exec. VP of R&D (Age 62, Pay $1.87M)
  • Mr. Chirfi Guindo, Exec. VP of Global Product Strategy & Commercialization (Age 54, Pay $1.32M)
  • Mr. Michael R. McDonnell, Exec. VP & CFO (Age 56)
  • Ms. Robin C. Kramer, VP & Chief Accounting Officer (Age 54)
  • Mr. Mark J. Hernon, Sr. VP & Chief Information Officer (Age 56)
  • Mr. Joe Mara, VP of Fin. & Head of Investor Relations
  • Ms. Natacha Gassenbach, Chief Communication Officer & Head of Corp. Affairs
  • Dr. Ginger Gregory, Exec. VP & Chief HR Officer (Age 52)

What is Biogen's stock symbol?

Biogen trades on the NASDAQ under the ticker symbol "BIIB."

Who are Biogen's major shareholders?

Biogen's stock is owned by a variety of retail and institutional investors. Top institutional investors include Gateway Investment Advisers LLC (0.04%), State of Alaska Department of Revenue (0.04%), Hexavest Inc. (0.03%), Traynor Capital Management Inc. (0.02%), 6 Meridian (0.02%) and Louisiana State Employees Retirement System (0.01%). Company insiders that own Biogen stock include Alexander J Denner, Alfred Sandrock, Brian S Posner, Michel Vounatsos, Robert W Pangia and Stephen A Sherwin.
View institutional ownership trends for Biogen
.

Which institutional investors are selling Biogen stock?

BIIB stock was sold by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, Hexavest Inc., Cullinan Associates Inc., Sowell Financial Services LLC, Gateway Investment Advisers LLC, Arden Trust Co, Investment House LLC, and Cypress Capital Group. Company insiders that have sold Biogen company stock in the last year include Alfred Sandrock, and Stephen A Sherwin.
View insider buying and selling activity for Biogen
or view top insider-selling stocks.

Which institutional investors are buying Biogen stock?

BIIB stock was purchased by a variety of institutional investors in the last quarter, including Louisiana State Employees Retirement System, Prairiewood Capital LLC, Traynor Capital Management Inc., OneAscent Financial Services LLC, NuWave Investment Management LLC, IFM Investors Pty Ltd, Strategic Investment Advisors MI, and KMG Fiduciary Partners LLC. Company insiders that have bought Biogen stock in the last two years include Alexander J Denner, and Michel Vounatsos.
View insider buying and selling activity for Biogen
or or view top insider-buying stocks.

How do I buy shares of Biogen?

Shares of BIIB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Biogen's stock price today?

One share of BIIB stock can currently be purchased for approximately $275.84.

How big of a company is Biogen?

Biogen has a market capitalization of $42.45 billion and generates $14.38 billion in revenue each year. The biotechnology company earns $5.89 billion in net income (profit) each year or $33.57 on an earnings per share basis. Biogen employs 7,400 workers across the globe.

What is Biogen's official website?

The official website for Biogen is www.biogen.com.

How can I contact Biogen?

Biogen's mailing address is 225 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-679-2000 or via email at [email protected]

This page was last updated on 1/18/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.